TW200640466A - Method of treatment - Google Patents
Method of treatmentInfo
- Publication number
- TW200640466A TW200640466A TW095100687A TW95100687A TW200640466A TW 200640466 A TW200640466 A TW 200640466A TW 095100687 A TW095100687 A TW 095100687A TW 95100687 A TW95100687 A TW 95100687A TW 200640466 A TW200640466 A TW 200640466A
- Authority
- TW
- Taiwan
- Prior art keywords
- related disorders
- disorders
- substance
- pharmaceutically acceptable
- limited
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 208000011117 substance-related disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 abstract 1
- 208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 208000003863 Marijuana Abuse Diseases 0.000 abstract 1
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 231100000643 Substance intoxication Toxicity 0.000 abstract 1
- 208000028505 alcohol-related disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 abstract 1
- 229950010883 phencyclidine Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 201000006152 substance dependence Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64226205P | 2005-01-07 | 2005-01-07 | |
| US73788705P | 2005-11-18 | 2005-11-18 | |
| US73786405P | 2005-11-18 | 2005-11-18 | |
| US73786505P | 2005-11-18 | 2005-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200640466A true TW200640466A (en) | 2006-12-01 |
Family
ID=36647771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095100687A TW200640466A (en) | 2005-01-07 | 2006-01-06 | Method of treatment |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1838325A1 (fr) |
| JP (1) | JP2008526839A (fr) |
| AR (1) | AR052191A1 (fr) |
| TW (1) | TW200640466A (fr) |
| UY (1) | UY29326A1 (fr) |
| WO (1) | WO2006073360A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007062339A2 (fr) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Formulations liquides |
| TWI488854B (zh) | 2008-06-20 | 2015-06-21 | Astrazeneca Ab | 二苯并噻氮呯衍生物及其用途 |
| US8389716B2 (en) | 2009-01-30 | 2013-03-05 | F.I.S. Fabbrica Italiana Sintetici S.P.A. | Process for the synthesis of quetiapine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US7071133B2 (en) * | 1993-11-16 | 2006-07-04 | Ppg Industries Ohio, Inc. | Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift |
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| SE0003126D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Method of treatment |
| WO2002062346A1 (fr) * | 2001-02-06 | 2002-08-15 | Astrazeneca Ab | Procede permettant de traiter l'abus d'une substance par de la quetiapine |
| US20060189599A1 (en) * | 2002-10-18 | 2006-08-24 | Green Alan I | Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking |
| AU2004253334A1 (en) * | 2003-07-02 | 2005-01-13 | Astrazeneca Ab | Metabolite of quetiapine |
| WO2005053619A2 (fr) * | 2003-12-04 | 2005-06-16 | The Research Foundation Of The City University Of New York | Effets de la clozapine et de la cocaine sur la liberation de dopamine et de serotonine dans le noyau accumbens pendant un comportement psychostimulant et sevrage |
| CA2550735A1 (fr) * | 2003-12-22 | 2005-07-14 | Acadia Pharmaceuticals Inc. | Analogues de diaryl[a,d]cycloheptene amino substitues utilises comme agonistes muscariniques, et procedes de traitement de troubles neuropsychiatriques |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
-
2006
- 2006-01-04 JP JP2007550327A patent/JP2008526839A/ja active Pending
- 2006-01-04 EP EP06700349A patent/EP1838325A1/fr not_active Withdrawn
- 2006-01-04 WO PCT/SE2006/000009 patent/WO2006073360A1/fr not_active Ceased
- 2006-01-05 UY UY29326A patent/UY29326A1/es not_active Application Discontinuation
- 2006-01-06 AR ARP060100058A patent/AR052191A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100687A patent/TW200640466A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY29326A1 (es) | 2006-08-31 |
| EP1838325A1 (fr) | 2007-10-03 |
| WO2006073360A1 (fr) | 2006-07-13 |
| AR052191A1 (es) | 2007-03-07 |
| JP2008526839A (ja) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006060507A3 (fr) | Procedes et compositions d'utilisation de composes immunomodulatoires pour le traitement des troubles d'immunodeficience | |
| MA28469B1 (fr) | Inhibiteurs de la dipeptidyle peptidase | |
| ATE548354T1 (de) | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen | |
| DK1879873T3 (da) | Neuroterapeutiske azolforbindelser | |
| EP2338490A3 (fr) | Combinaisons utiles pour le traitement de désordres neuronales | |
| NZ592544A (en) | Isonicotinamide orexin receptor antagonists | |
| WO2007041365A3 (fr) | Composes organiques | |
| WO2004037169A3 (fr) | Inhibiteurs de dipeptidylpeptidase heterocyclique beta-amino destines au traitement ou a la prevention de diabetes | |
| ATE397930T1 (de) | Verwendung von oxazolidinon-chinolin-hybrid- antibiotika zur behandlung von anthrax und anderen infektionen | |
| GB0225474D0 (en) | Therapeutic agents | |
| WO2006017673A3 (fr) | Influence du taj sur les fonctions neuronales | |
| WO2007006003A3 (fr) | Combinaisons d'eszopiclone et de trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine, et methodes de traitement de la menopause et des troubles de l'humeur, de l'anxiete et troubles cognitifs | |
| TW200640466A (en) | Method of treatment | |
| MY142252A (en) | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods | |
| EP2543384A3 (fr) | Traitement des conditions impliquant la démyélinisation | |
| DE602004015089D1 (de) | Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika | |
| TW200616644A (en) | Medicine for prevention or treatment of diabetes | |
| TW200503726A (en) | Use of dihydroimidazolones for the treatment of dogs | |
| WO2021247916A8 (fr) | Composés d'azétidine et de spiroazétidine et leurs utilisations | |
| ATE326223T1 (de) | Methode zur behandlung der hyperaktiven blase | |
| WO2005007239B1 (fr) | Utilisation de la dapsone comme neuroprotecteur dans l'infarctus cerebral | |
| WO2005097111A3 (fr) | Traitement des tremblements utilisant des agonistes inverses de l'histamine h3 ou des antagonistes de l'histamine h3 | |
| MXPA04004743A (es) | Derivados de 2,3-diaril-pirazolidina activos hacia neurotensina. | |
| WO2004016604A3 (fr) | Composes azabicycliques comme agents actifs du systeme nerveux central | |
| AU5857899A (en) | Use of tgf-beta inhibitors for treating cerebral disorders |